A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

NCT03595124 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

NIH

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Stage IV Renal Cell Cancer AJCC v8
TFE3-Rearranged Renal Cell Carcinoma
Unresectable Renal Cell Carcinoma

Interventions

DRUG: Axitinib
BIOLOGICAL: Nivolumab

Sponsor

National Cancer Institute (NCI)